Abbott Laboratories Corporation

Abbvie Inc.

Hwan-soo Jae

Martin Winn

Bryan K Sorensen

Steven Armen Boyd

Andrew Stewart Tasker

Thomas W Von Geldern

Charles W Hutchins

Jeffrey A Kester

Gang Liu

Kenneth J Henry

James T Link

Steven J Wittenberger

Steven A King

Bruce G Szczepankiewicz

Jyoti R Patel

Hong Yong

Jeffrey J Rohde

Marina Pliushchev

Qi Shuai

Dariusz Wodka

Peer Jacobson

Michael E Brune

Jiahong Wang

Lynne E Rueter

Kaitlin E Browman

R Scott Bitner

Yixian Chen

Biswanath De

Karla Drescher

Karsten M Wicke

Vince S Yeh

David J Madar

Jurgen Dinges

Ravi Kurukulasuriya

Marina I Strakhova

Steven Fung

Jacob J Plattner

Hing L Sham

Le Wang

Kenneth Jay Barr

Zhili Xin

Zhonghua Pei

Keith W Woods

Gui-Dong Zhu

William R Baker

Qun Li

Douglas M Kalvin

Indrani W Gunawardana

Sheldon Wang

Thomas M Zydowsky

Tom W Von Geldern

Stephen L Gwaltney, Ii

John K Lynch

Michael A Staeger

Akiyo K Claiborne

Jennifer C Freeman

Robert J Padley

Todd J Janus

Yixian Long

Edwin De Lara

Robert C Goldman

A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-&#x3b2;-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Treatment of central nervous system disorders

The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Endothelin antagonists

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.

A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

Treatment of diseases using endothelin antagonists

Oxazoline antiproliferative agents

A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Growing community of inventors

Glencoe, IL, United States of America

Hwan-soo Jae